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Recently, agonistic autoantibodies (agAAb) activating the β2-adrenergic receptor were
detected in primary open-angle glaucoma (POAG) or ocular hypertension (OHT)
patients and were linked to intraocular pressure (IOP) (1). The aim of the present
study was to quantify β2-agAAb in the sera of glaucoma suspects and patients with
primary and secondary glaucoma. Patients with OHT (n = 33), pre-perimetric POAG
(pre-POAG; n = 11), POAG (n = 28), and 11 secondary OAG (SOAG) underwent
ophthalmological examinations including examinations with Octopus G1 perimetry and
morphometry. Twenty-five healthy individuals served as controls. Serum-derived IgG
samples were analyzed for β2-agAAb using a functional bioassay. The beat-rate-increase
of spontaneously beating cultured neonatal rat cardiomyocytes was monitored with
1.6 beats/15 s as cut-off. None of the sera of normal subjects showed β2-agAAb. In
POAG or OHT patients increased beating rates of 4.1 ± 2.2 beats/15 s, and 3.7 ±
2.8 beats/15 s were detected (p > 0.05). Glaucoma patients with (POAG) and without
perimetric (pre-POAG) defects did not differ (pre-POAG 4.4 ± 2.6 beats/15 s, POAG
4.1 ± 2.0 beats/15 s, p > 0.05). Patients with SOAG yielded mean beating rates of 4.7
± 1.7 beats/15 s (p > 0.05). β2-agAAb were seen in 73% of OHT, 82% of pre-POAG,
82% of POAG, and 91% SOAG patients (p < 0.001). Clinical data did not correlate
with beating rate (p > 0.05). The robust β2-agAAb seropositivity in patients with OHT,
pre-POAG, POAG, and SOAG suggest a primary common role for β2-agAAb starting
early in glaucoma pathophysiology and turned out to be a novel marker identifying all
patients with increased IOP independent of glaucoma stage and entity.
Keywords: autoantibodies, glaucoma, ocular hypertension, β2-adrenergic receptor, primary open-angle
glaucoma, secondary open-angle glaucoma
INTRODUCTION
The pathophysiology of glaucoma is known to be multifactorial. In addition to oxidative stress (2),
vascular dysregulation (3), or morphological alterations of the trabecular meshwork (4), several
further factors may be involved. Intraocular pressure (IOP) is the main risk factor for glaucoma.
However, patients with glaucoma developed progressive disease despite optimal pharmaceutical
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and surgical IOP lowering therapies (5). The β2-adrenergic
receptors (β2AR) is likely be involved in glaucoma pathogenesis,
as topical application of the β-blocker timolol is an important
module of anti-glaucomatous therapies. β2AR are to be found
on several ocular tissues. β2AR is expressed by cells of the
trabecular meshwork and the ciliary body, responsible for
outflow and secretion of aqueous humor (AH), respectively
(6, 7). Furthermore, microvessels and optic nerve tissue (8–10)
reportedly express β2AR and thus influencemicrocirculation and
neurons, respectively.
Recently, we described specific agonistic autoantibodies
(agAAb) activating the β2AR (β2-agAAb) in patients with
primary open-angle glaucoma (POAG) and ocular hypertension
(OHT). We hypothesize that autoimmunity contributes to the
etiopathogenesis of glaucoma. Adsorption of β2-agAAb may
influence production and outflow of aqueous humor and,
consequently, IOP (11).
The exact role of agonistic agAAb activating adrenergic
receptors in disease is still elusive. Chagas’ disease (12), allergic
asthma (13), idiopathic dilated cardiomyopathy (13) in patients
with heart failure (14) are associated with agonistic agAAb.
Furthermore, in sera of patients, who suffer from Alzheimer’s or
vascular dementia β2-agAAb have been reported (15). The β2-
agAAb, observed in patients with POAG or OHT, were directed
against the second extracellular loop of β2AR (peptides 181–187
and 186–192); the major subclass was IgG3. In a principal-of-
proof study IOP decreased transiently after unspecific removal by
immunoadsorption of IgG, including the potentially pathogenic
β2-agAAb (1). These observations lead us to postulate the
hypothesis of an involvement of agonistic β2-agAAb in the
pathogenesis of glaucoma. The aim of the present study was to
investigate the distribution of agonistic β2-agAAb in glaucoma
suspects and in patients with primary and secondary open-
angle glaucoma.
MATERIALS AND METHODS
Patients
One hundred-eight individuals were recruited from the
Department of Ophthalmology and Eye Hospital, Friedrich-
Alexander-University Erlangen-Nürnberg [Erlangen Glaucoma
Registry, ISSN 2191-5008, CS-2011; NTC00494923 (5)].
We recruited 33 patients with OHT (54.8 ± 12.8 years, 17
female, 16 male), 11 pre-perimetric POAG (58.8 ± 10.9 years,
5 female, 6 male), 28 POAG (62.2 ± 13.7 years, 11 female,
17 male), and 11 SOAG (50.6 ± 12.5 years, 3 female, 8 male;
6 pigmentary glaucoma, PG; 5 Pseudoexfoliation glaucoma,
PEXG). Twenty-five healthy subjects served as controls.
The probands underwent a complete ophthalmological
examination including slit-lamp biomicroscopy, funduscopy,
and white-on-white perimetry (Octopus 500, Interzeag,
Schlieren, Switzerland; program G1). IOP was measured by
Goldmann applanation tonometry at five times of the day
(10.00 a.m., 12.00 a.m., 4.00 p.m., 9.00 p.m., and 12.00 p.m.).
The retinal nerve fiber layer thickness, RNFL, was quantified
by Spectralis Optical Coherence Tomography (Spectralis R©
OCT Version 1.9.10.0, Heidelberg Engineering, Heidelberg,
Germany). The study protocol was done in accordance with the
tenets of the Declaration of Helsinki and was approved by the
Local Ethic Committee.
Control Subjects
Controls were screened with slit-lamp biomicroscopy,
tonometry, fundoscopy, and papillometry for normal values.
Ocular Hypertension (OHT) Patients
Patients with OHT had an increased IOP (>21 mmHg,
confirmed at least once), yet no sign of glaucomatous optic
disc alterations, and normal perimetric white-on-white findings
(G1 perimetry).
Primary Open-Angle Glaucoma (POAG) Patients
Diagnosis of POAG was based on an open anterior chamber
angle, IOP > 21 mmHg (confirmed at least once), and a
glaucomatous optic disc, classified after Jonas (16). Additionally,
functional perimetric field loss had to be confirmed at least once
according to the following criteria:
(I) at least three adjacent test points having a deviation ≥5
dB and with one test point with a deviation >10 dB lower than
normal, or (II) at least two adjacent test points with a deviation
≥10 dB, or (III) at least three adjacent test points with a deviation
≥5 dB abutting the nasal horizontal meridian or (IV) a mean
visual field defect of>2.6 dB.
Secondary Open-Angle Glaucoma (SOAG) Patients
Secondary open-angle glaucoma (SOAG) were classified
according to POAG, yet with additional PEX material (PEXG)
or pigmentary dispersion (PG). Additionally, SOAG patients
displayed loss of the visual field, according to the before
mentioned criteria (see POAG).
Primary Pre-perimetric Open-Angle Glaucoma
(pre-POAG) Patients
Patients with pre-POAG showed the same morphological
findings like those with POAG, however, their visual field was
(still) normal.
Affinity Purification of agAAb
Affinity purification of agAAb was done by a biotinylated
peptide biotin-AINCYANETCCD corresponding to the second
extracellular loop of the β2AR. After incubation of 1ml IgG
with 300 µl of the peptide (100µg/ml; for 1 h), this procedure
was followed by an incubation with streptavidin-coated magnetic
particles (Roche, Germany; for 30min). The separation was
performed with a magnetic separator (Dynal, Germany). After
washing with PBS, eluation with 3M KSCN in two 0.5ml
steps was done. Afterwards the agAAb were dialyzed with PBS
(48 h, 4◦C).
Cardiomyocyte Bioassay
Cardiac myocytes were prepared from heart ventricle of 1–
2 day-old Sprague-Dawley rats (13). By digestion with a
0.25% solution of crude porcine trypsin (Serva, Germany)
the myocardial cells were dispersed and suspended in SM20-
I medium (Biochrom, Germany), which contained penicillin
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FIGURE 1 | β2-agAAb in patients with OHT, primary, and secondary
glaucoma. Cardiomyocyte beating rates [beats/15 s] modulated by IgG from
sera of control subjects (normal healthy donor, NHD), patients with ocular
hypertension (OHT), pre-perimetric POAG (primary open-angle glaucoma),
POAG, and SOAG (secondary open-angle glaucoma) (cut-off 1.6 beats/15 s);
cardiomyocyte beating rate is counted as difference of the baseline value (i.e.,
spontaneously beating rate of cultured cardiomyocytes) and the activated
beating rate after addition of the test samples; therefore, some negative values
were recorded.
(Heyl, Germany), 10% heat-inactivated neonatal calf serum
(Gibco, Germany), glutamine (Serva, Germany), streptomycin
(HEFA Pharma; Germany), hydrocortisone (Merck, Germany),
and fluorodeoxyuridine (Serva, Germany). After seeding the
cardiomyocytes with a field density of 160.000 cells/cm2, the
culture medium was refaced after 24 h. The cells were cultured
for 3–4 days at 37◦C previous to stimulation. Two hours before
onset of the experiments, the medium was renewed with fresh
culture solution. Target point was the beating rate for 15 s of
7–10 selected cardiomyocte cells or synchronously contracting
cell clusters per flask, placed on a heated stage inverted
microscope at 37◦C (basal contraction rate: 162 ± 4 beats/min).
The cardiomyocytes were incubated with the IgG fractions of
probands’ sera (duration: 60min; dilution of 1:40). The target
was loop II (HWYRATHQEAINCYANETCCDFFTNQ). The
two epitopes were AINCYAN (AS181–187) and ANETCCD
(AS186–192).
Statistical Analysis
Statistical analysis was done using SPSS (version 21.0). Data
are displayed as mean ± standard deviation and percentages.
Mann-Whitney-U-tests were calculated. Correlation analyses
were performed.
RESULTS
The data of this study is displayed in Figure 1 and Table 1. The
beating rate of the cardiomyocytes was 0.15 ± 0.5 beats/15 s
in normal subjects. However, patients with glaucoma yielded
significant alterations of the cardiomyocytes in the bioassay:
patients with OHT and POAG showed increased beating rates of
TABLE 1 | Mean beating rates [beats/15 s], absolute number and percentage of
β2-agAAb seropositivity of ocular hypertension (OHT), pre-perimetric POAG
(pre-perimetric primary open-angle glaucoma), POAG, and SOAG patients in
comparison to control subjects. Level of significance was reached for all observed
patients’ group compared to control.
Control OHT Pre-
POAG
POAG SOAG
Beats/15 s 4.1 ± 2.2
0.15 ± 0.5 3.7 ± 2.8 4.4 ± 2.6 4.1 ± 2.0 4.7 ± 1.7
p-Values to control <0.001** <0.001** <0.001** <0.001**
n 25 33 11 28 11
Seropositive 0 24 9 23 10
% Seropositive 0 73 82 82 91
**Significant p < 0.001, Mann-Whitney-U-test.
3.7± 2.8 and 4.1± 2.2 beats/15 s, respectively. Subgroup analysis
for patients with glaucoma with (POAG) and without visual field
defect (pre-perimetric POAG) showed mean beating rates of 4.4
± 2.6 beats/15 s (pre-perimetric POAG) and 4.1 ± 2.0 beats/15 s
(POAG). Patients with SOAG yielded mean beating rates of 4.7
± 1.7 beats/15 s. Subdividing into PEXG and PD showed mean
beating rates of 5.2 ± 0.8 beats/15 s and 4.2 ± 2.2 beats/15 s,
respectively. No difference in beating rates was seen for group
and subgroup analysis (p> 0.05, Mann-Whitney-U-test).
With the cut-off value of 1.6 beats/15 s, β2-agAAb were to
be observed in 24/33 (73%) of patients with OHT, 9/11 (82%)
with pre-perimetric POAG, and 23/28 (82%) with POAG. SOAG
patients yielded agAAb in 10/11 (91%). Subdivision into PD and
PEXG showed 5/6 (83%) and 5/5 (100%), respectively (Figure 1).
Clinical data of all patients’ groups can be seen in Table 2.
Beating rates of β2-agAAb seropositive patients showed no
correlation with morphometric measurements (RNFL; p > 0.05)
and functional parameters (mean defect MD; loss variance LV p
> 0.05). Additionally, no correlation was seen for beating rate
of β2-agAAb seropositive patients and maximum IOP of the day
of examination (p > 0.05). Additionally, not a single significant
correlation was to be observed for the stages of glaucoma disease
and beating rates (p > 0.05). Subgroup analysis yielded no
significant correlation of beating rates with MD in POAG, SOAG
(p > 0.05), respectively. Additionally, beating rates showed no
correlation with maximum IOP of the day of examination in
β2-agAAb seropositive OHT, pre-perimetric POAG, POAG, and
SOAG (p > 0.05). RNFL was not correlated with beating rates in
β2-agAAb seropositive pre-perimetric POAG, POAG, and SOAG
(p> 0.05). Thus, the beat rate discriminated between all patients
with increased IOP independent of glaucoma stage and entity.
DISCUSSION
As shown in a previous study, pathophysiology of glaucoma
is multifactorial and includes immunological components (1).
Agonistic β2-agAAb were to be observed in sera of patients
with OHT and POAG. Transient removal of circulating IgG
including the agAAb transiently reduced the IOP, suggesting a
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TABLE 2 | Clinical data of OHT (ocular hypertension), pre-perimetric POAG (primary open-angle glaucoma), POAG, and SOAG (secondary open-angle glaucoma)
patients: best corrected visual acuity (BCVA), disease stage (classified after Jonas), retinal nerve fiber layer thickness (RNFL), mean defect (MD), loss variance (LV), and
maximum IOP (IOPmax).
BCVA Stage of disease RNFL [µm] MD [dB] LV [dB2] IOPmax [mm Hg]
OHT 0.93 ± 0.1 – 93.5 ± 16 −0.05 ± 1 2.5 ± 1.2 19.9 ± 4
Pre-POAG 0.95 ± 0.2 1.5 ± 0.9 78.5 ± 16 −0.05 ± 2 4.3 ± 3.7 19.0 ± 6
POAG 0.77 ± 0.2 2.3 ± 1.0 80.5 ± 98 7.9 ± 7 38.9 ± 26.4 17.8 ± 5
SOAG 0.65 ± 0.3 2.8 ± 1.0 60.6 ± 18 12.8 ± 8 50.5 ± 28.1 18.0 ± 4
None of the glaucoma follow-up parameters correlated significantly with the activity of the agAAb (p > 0.05).
link between β2-agAAb and IOP. As a cardiomyocyte bioassay
detects the presence and function of autoantibodies, this method
was used with the focus of showing functional active β2-agAAb.
In the present study, we screened sera of glaucoma suspects and
patients with primary and secondary glaucoma for the presence
of functional active β2-agAAb. A percentage of 82 of POAG
patients, and 91 of SOAG patients showed these β2-agAAb,
whereas all healthy donors were seronegative. As β2-agAAb were
also to be detected in sera of pre-perimetric POAG, and OHT
patients, β2-agAAb, we assume that β2-agAAb are involved in the
early etiology of glaucoma by a shared mechanism.
Immunological mechanisms were hypothesized to operate
in glaucoma disease by several studies (17–19). However,
the exact pathomechanisms of this neurodegenerative disease
are still elusive. An elevated, not regulated IOP is known
to be the major risk factor for onset and progression of
glaucoma. Yet, most of patients with glaucoma show a disease
progression despite optimal conservative and surgical IOP
lowering therapies (5). Thus, several other factors contribute
to its multifactorial pathogenesis (e.g., oxidative stress, vascular
dysregulation) (20, 21).
It is supposed that agonistic β2-agAAb influence IOP (1), as
therapy with β-blockers is common in clinical praxis. Increased
IOP is caused by an imbalance between production and outflow
of AH, both influenced by β2-agAAb. Experimental data showed
that catecholamines can increase AH flow (22). Epinephrine
induced AH flow, especially at nighttime (day: 15%: night 47%)
(23). The molecular target for these clinical observations can be
seen in the activity, expression and regulation of the Na-K-Cl co-
transporter. As isoproterenol, a non-selective βAR agonist, is able
to stimulate chloride transport via the ciliary epithelial layer (24)
and Na-K-Cl co-transporter activity in pigmented ciliary body
(25), it is justified to assume an influence of adrenergic agonists
on the Na-K-Cl cotransporter in the ciliary body.
Considering the adrenergic subtype, application of a specific
β2-blocker (ICI 118.551) diminished the stimulation of theNa-K-
Cl co-transporter. We hypothesize that β2-agAAb hyperactivate
the Na-K-Cl co-transporter in the ciliary body, as a similar effect
of epinephrine on Na-K-Cl co-transporter activity was reported
and this stimulation was inhibited by blocking the β2AR (25).
The Na-K-Cl co-transporter activity then causes an increased
AH flow especially at nighttime. This hypothesis is supported by
clinical data of increased AH flow in OAG patients compared to
normal subjects during the night hours (26). The Na-K-Cl co-
transporter of the trabecular meshwork (TM), the main outflow
pathway of AH, is a further potential target of the β2-agAAb
which expose βAR predominantly of β2-subtype (7, 27, 28).
Changes in the pore sizes of the TM, and thus of the AH
outflow, were influenced by swelling and shrinkage of TM cells.
The Na-K-Cl co-transporter is supposed to be a major regulator
of the cellular volume and monolayer permeability regulation
of TM cells, via ion transport (29). Inhibition and stimulation
of the Na-K-Cl co-transporter in human TM cells leads to a
reduction and increase of the volumes of TM cells, respectively
(29). In cultured glaucomatous TM cells the cellular volume was
reportedly enlarged when compared with healthy tissues and
is reduced after incubation with bumetanide, a blocker of the
Na-K-Cl co-transporter (30). Consistent with this finding the
inhibition of the Na-K-Cl-co-transporter in human TM cells also
led to an increased AH outflow facility (31). We hypothesize
that β2-agAAb stimulate the Na-K-Cl-co-transporter in the TM
cells, increase the TM cell volume with a consecutive decrease of
extracellular space and outflow. This elevates the IOP.
β2AR are also present on pericytes and thus β2-agAAb may
also influence the vascular microcirculation. Activation of β2AR
on retinal blood vessels reportedly induce vasodilatation in vivo
(32). A “direct” autonomic innervation is not present in retinal
blood vessels (33). Yet, sympathetic activation can activate β2AR
“indirectly” via its transmitter adrenaline (34). Especially, β2- and
β3AR agonists have been shown to mediate retinal vasodilatation
(35). According to the current data available in literature, β2AR
mediate vasodilation and regulate the retinal microcirculation.
We hypothesize that β2-agAAb mediated changes in retinal
microcirculation further contributes to onset and progression of
glaucoma, as blood flow in the optic nerve head and choroid were
reduced in patients with POAG and OHT (36).
β2AR of human astrocytes and neurons of the optic nerve
(9) are a third candidate target of β2-agAAb. After optic nerve
transection in rabbits and rats, β2AR expression increased and
peaked 90 days after intervention (9). A regulative function of
astrocyte-borne β2AR has been assumed, as immature astrocytes
suppressed glial scar formation (9, 37). Further support for this
hypothesis was provided by an in vivo study on neuronal damage
showing a reduced astrocyte hypertrophy and consecutive glial
scar formation after application of βAR antagonists (38). Recent
data showed that just an elevated IOP induced oxidative stress
(via reduction in glutathione), axon degeneration of the optic
nerve head and autophagy in the retinas. Thus, hypoxic glial
cells can be detected in animals with OHT, even in the absence
of a glaucomatous pathology (39). β2AR of astrocytes were also
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involved in the regulation of the glucose metabolism (40, 41) and
are discussed to contribute to neuronal degeneration (42, 43).
In summary, β2-agAAb influence three factors of onset and
progression of glaucoma: IOP, retinochoridal microcirculation as
well as astrocyte and neuronal degeneration. All these targets are
common findings in patients with OHT and POAG. Thus, β2-
agAAb seemed to be a very early factor in the etiopathogenesis
of glaucoma disease. Autoantibodies are hallmarks of a plethora
of chronic diseases, like systemic lupus erythematosus (SLE)
(44), refractory hypertension (45), type 2 diabetes (46), and
dementia (15). Agonistic autoantibodies usually belong to the
IgG subclasses 1–3. They are characterized by their binding
to the extracellular loop 1 or 2 of neighboring G protein-
coupled receptor molecules (GPCRs). This homodimerization
non-canonically activates them in a manner similar to their
natural ligands (47).
In contrast to the short-term activating canonical agonists,
the binding of the agAAb delivers a rather stable signal, as
observed in cell culture with neonatal rat cardiomyocytes.
The uncontrolled, prolonged activation of the GPCR and its
pathophysiological consequences was intensively investigated,
especially for the AR. In a rat model, the cardiotoxic effects of
agAAb against ß1AR have been demonstrated (48). Accordingly,
fragments from the loop 2 of the β1AR induce dilated
cardiomyopathy (DCM), also frequently associated with these
agAAb in humans. In most autoimmune diseases, the pathogenic
contribution of the agAAb is still elusive. Relatively clear
clinical findings are present in DCM. Therapeutic apheresis
(immunoadsorption) not only removed agAAb against the ß1AR
from the bloodstream but also improves cardiac output for
months (49). The main therapeutic target in glaucoma is the
elevated IOP. Reduction of each single mmHg delays glaucoma
onset and/or progression (50). Previously we reported that
unspecific adsorption of IgG was accompanied by a transient
decrease of IOP in patients, refractory to maximal conservative
therapies (1). We argue that a specific elimination of β2-
agAAb is a candidate option for the therapy of medical
refractory glaucoma.
Glaucoma can be detected in up to 13% of patients with
SLE. This may be caused by (I) a general predisposition
to autoimmunity, (II) the interaction of the various AAb
and agAAb, and (III) the therapeutic administration of
glucocorticoids (51, 52). It is of interest to analyze the
consequences of the interaction of different agAAb being
simultaneously present in a patient.
Functional active agonistic autoantibodies directed against
the GPCR are measured by using a cardiomyocyte bioassay, yet
alternatives failed until now. However, western blot, immune
precipitation and ELISA were unable to discriminate between
agonistic autoantibodies and those that merely bind the
autoantigene. None of the assays, including ours (unpublished)
were able to reliably identify the agonistic antibodies. This
might be due to the potential different conformation of human
recombinant receptors (β2AR) compared to the highly steric
specific epitope, binding agAAb. Additionally, the molecular
weight of the antibody binding loop peptide (instead of the whole
ß2AR) is too low for precipitation.
CONCLUSION
Immunologic factors are increasingly being discussed to be
involved in the etiopathogenesis of glaucoma (1, 17). Here
we present data on β2-agAAb seropositivity in patients with
POAG, SOAG, pre-perimetric POAG, and OHT and argue for
a critical role of β2-agAAb already in an early asymptomatic
phase of glaucoma disease. Further studies are justified to
clarify the molecular basis of the β2-agAAb in glaucoma disease
and therapy.
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